List of Peptide Therapies Companies in France - 16

4Moving Biotech is a clinical-stage biopharmaceutical company founded in 2020. We are committed to develop first-in-class breakthrough therapies for the millions of patients suffering from osteoarthritis (OA) in the world. 4Moving Biotech is a subsidiary of 4P-Pharma, an innovation accelerator biotech company.

AdipoPharma SAS is a French biotech company with a US subsidiary committed to understanding the role of the adipocyte cells in diabetes via their unique effect on lipid biosynthesis and management of whole-body lipid homeostasis. Our first-in-class candidate - PATAS - is set to enter clinical trials later this year.

Axoltis pharma is a biopharmaceutical company dedicated to develop a first-in-class disease-modifying drug to treat patients with neurodegenerative or traumatic neurological disorders with high unmet medical needs. Our innovative approach: combining Preventative, Neuroprotective, Regenerative & Remodeling properties in a single drug, as the key to cure complex neurological disorders. Our products are first-in-class multifunctional peptides with high potential in many CNS disorders.

Corteria Pharmaceuticals - FOCUSED ON THE DEVELOPMENT OF TRANSFORMATIVE THERAPIES FOR THE TREATMENT OF WORSENING AND ACUTE DECOMPENSATED HEART FAILURE Founded in 2021, Corteria Pharmaceuticals is a privately held company developing first-in-class drugs for indications of high unmet medical need, such as heart failure, sarcopenia and obesity subpopulations. Our strategy implies innovative patient stratification and target selection based on human evidence and a better understanding of the disease biology in patients. We are using cutting-edge methods to stratify the patients and identify those who will benefit the most from our treatments. Our focus is on worsening and acute heart failure, right heart failure, sarcopenia (including age-related sarcopenia and obesity-related sarcopenia) and obesity with established complications.

CSBio is a leading peptide and peptide synthesizer manufacturing company located in Silicon Valley, California. For over 30 years, CSBio has been producing automated peptide synthesizers, high quality custom peptides, and cGMP peptides for the global pharmaceutical community. Our peptide products and peptide synthesis equipment can be found in peptide production laboratories and pharmaceutical companies worldwide.

Evora Biosciences develops novel immunomodulatory peptides with the aim to bring first-in-class treatments to patients in areas of high unmet need.

GlioCure, a spin-off company of Angers and McGill Montreal universities, aims to treat glioblastoma that causes 200,000 deaths worldwide each year. To overcome this challenge, GlioCure is hyper-specialized and develops glioblastoma-specific drugs. GlioCure is currently focusing on the development of GC01, an anti-glioblastoma peptide discovered by Joël Eyer, Director of Research from INSERM, and covered by two patent families for which GlioCure owns worldwide exclusive rights. GlioCure's team has the experience and the know-how to ensure the successful completion of GC01’s development plan: Louis-Marie is a biotech entrepreneur with 15 years of experience in the field of innovative therapies and rare diseases; Claire, specialist of the neuronal cytoskeleton, has sound knowledge of preclinical experimental techniques; Its Scientific & Medical Advisory Board is composed of leading international experts in research and treatment of glioblastoma.

Inotrem is a biotechnology company specialized in immunotherapy for acute inflammatory syndromes, such as septic shock. Founded in 2013, with offices in Paris and a technology center in Nancy (France), the company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Leveraging its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, nangibotide, with applications in a number of therapeutic indications such as septic shock or myocardial infarction. Next to acute inflammatory syndromes, Inotrem is also developing a program targeting chronic inflammatory diseases.

Jalon Therapeutics aims to develop innovative therapies that inactivate yet untargeted vital tumor signaling pathways. Our mission is to develop medicines that will transform the lives of people fighting cancer. For that purpose, we leverage our deep understanding of stress-related protein-protein interaction networks that sustain the malignant phenotype while not being necessary for normal cells. This mechanism, defined as “non-oncogene addiction” (NOA), offers potential novel, safer and more effective therapeutic strategies. Jalon Therapeutics is rooted in pioneering fundamental research and clinical investigations from INSERM laboratories and Saint-Louis Hospital in Paris. Jalon Therapeutics was cofounded in 2021 by Jean-Luc Poyet, Prof. Martine Bagot, Prof. Hervé Dombret, Jérôme Tiollier, Jean-Christophe Rain and Philippe Salphati. Among the proteins involved in non-oncogene addiction, the scaffold protein AAC-11 (Anti-Apoptosis Clone-11) is a cornerstone component of the signaling networks essential for cancer cell survival, adaptation to stress, resistance to therapies, immune evasion and metastatic potential. Derived from AAC-11, JRT39 is the first-in-class lead candidate developed for the treatment of hard-to-treat cancers. JRT39 properties combine the broad tissue distribution and cell permeability of small molecules with the excellent specificity and target-engagement potency of antibodies, together with unique modes of action. As such, JRT39 stands as breakthrough discovery to treat advanced and refractory cancers, alone or in combination with other treatment modalities. Furthermore, Jalon Therapeutics is building a drug discovery platform to develop other candidates derived from AAC-11 and AAC-11 partners for the treatment of cancer.

Meddenovo offers a unique blend of AI technologies and molecular modeling to increase efficiency and success in drug development processes. Our technological platform, including bioAIM and focAlyze, delivers unparalleled drug candidate potency assessment and optimization of drug-like properties. In addition to designing small organic molecules, our proficiency in peptide-based medicine and metal chelators extends beyond traditional boundaries, offering a competitive advantage in creating solutions for novel drug research and development studies. In our integrated drug discovery services, we create a unique chemical space specific to your biological targets. We use our focAIyze module to explore druggability or any specific physiochemical property your project might need of the created chemical space. With our physics-based AI-supported software bioAIM, we screen the target with great accuracy. bioAIM, utilizing its unique blind docking capability, reveals precise binding sites and gauges the potency of molecules, ensuring compatibility with complex entities such as DNA or ribosomes. We also provide custom computational solutions using our modular tools to predict drug resistance bound to mutations, elucidate biochemical reaction mechanisms, and calculate metal affinity analysis. Meddenovo strives for precision and reliability in drug discovery, providing a refined approach to developing groundbreaking medicines with reduced failure rates and improved outcomes.

MElkin pharmaceuticals is a biopharmaceutical company identifying and developing innovative new treatments for cancer and brain diseases that are associated with aberrant activation of the MAPKinase/ERK signaling pathway. Founded in 2015, the company is currently engaged in the preclinical development of the PepFos lead compound for cancer treatment.

Nosopharm is an innovative biotechnology company headquartered in Lyon (France) and specialized in the research and development of new molecules to combat antimicrobial resistance (AMR). The mission of Nosopharm is to discover and develop novel first-in-class anti-infectives addressing unmet medical needs. The innovative anti-infective drug discovery platform developed by Nosopharm is based on the therapeutic exploitation of a very original bioresource: the bacterial genera Xenorhabdus and Photorhabdus.

‘OT4B was created in 2017, at the initiative of the French Prader-Willi community, to support and continue the academic research work of the team led by Professor Maithé Tauber from the National Reference Centre for Prader-Willi Syndrome at the Toulouse University Hospital*, and ongoing in France since 2007. In partnership with the Toulouse University Hospital, our objective is to develop oxytocin as the first treatment for patients with Prader-Willi syndrome and to make it available as soon as possible to the widest number of patients in order to improve the daily life and future of both patients and their families.’

PEP-Therapy is a clinical-stage biotechnology company developing first-in-class peptides as targeted therapies in oncology. PEP-010, first drug candidate, is a pro-apoptotic agent which has demonstrated anti-tumor efficacy in a number of pre-clinical models and a good safety profile. PEP-010 is currently evaluated in a Phase Ia/b clinical trial in patients with recurrent and/or metastatic solid tumors. PEP-Therapy was founded in 2014 and builds on research results from Institut Curie and Sorbonne University. The company is backed by international investors.

PeptiMimesis is a strategic partner in the design, the discovery and the early development of transmembrane therapeutic peptides.

ProteoGenix is a leading life sciences organization which provides services in molecular biology and immunology and in particular polyclonal and monoclonal antibody development, recombinant protein expression and purification, peptide synthesis as well as gene synthesis. ProteoGenix’s commitment to its clients is to ensure the access to comprehensive and integrated solutions to help our customers develop the tools they need to efficiently conduct their biology and research projects in a time effective manner. Beginning with the synthesis of the gene ProteoGenix develops all the materials required for immunoassay services. Proteogenix’s exceptional and functional expertise combined with our extensive scientific knowledge and experience ensures ProteoGenix to be a reliable partner for your antibodies, proteins, genes (cDNA) and peptides. Our custom services ensure a unique and tailored process to our clients revolving around four areas : Protein expression and purification in E. Coli, Yeast, Insect cells (baculovirus) and Mammalian Cells Monoclonal antibody production and Polyclonal antibody production Gene synthesis, sub-cloning and mutagenesis Peptide synthesis, purification and conjugation ProteoGenix also provides the research and academic communities with a wide range of commercial products available on our website such as antibodies, proteins, ELISA kits, tissue microarrays, chimera RNAi, molecular biology products as well as many more.